Clinical efficacy of combination therapy of Tamsulosin plus Tolterodine sustained-release capsules on benign prostatic hyperplasia with overactive bladder in elderly men

Abstract

Objective To evaluate the efficacy of combination therapy of cholinergic receptor blocker Tolterodine and Alpha-adrenergic receptor blocker Tamsulosin sustained-release capsules on benign prostatic hyperplasia(BPH)with overactive bladder(OAB)in elderly men. Methods A total of 97 male BPH patients aged 80 years and over(80~98 years old, mean 87.7 years old)were enrolled in this study, who met the diagnosis and treatment guidelines of OAB formulated by Chinese Urological Association and were admitted to our hospital from Jan. 2015 to July. 2015. Patients were randomly divided into Tamsulosin group(n=51, treated with Tamsulosin)and combination group(n=46, treated with Tamsulosin and Tolterodine). Results In Tamsulosin group after treatment, the international prostate symptom score(IPSS)was reduced from(18.3±2.7)to(13.3±3.1)(t=14.94, P 0.05). The total incidences of adverse events(mainly mouth dryness)had no significant differences between the Tamsulosin group and the combination group(8.7% vs. 5.9%, χ2=99.47, P>0.05). No acute urinary retention was found in the two groups. Conclusions The combination therapy of Tamsulosin and Tolterodine has better efficacy and safety than single Tamsulosin application in the treatment of BPH with OAB in elderly men. Key words: Prostatic hyperplasia; Urinary bladder, overactive; Muscarinic antagonists; Adrenergic alpha- antagonists